Summary of Conference Call on Fenebrutinib and Multiple Sclerosis Pipeline Company and Industry Overview - The conference call focused on the phase 3 FENtrepid results for fenebrutinib, a treatment for primary progressive multiple sclerosis (PPMS), presented at ACTRIMS 2026. The discussion also included updates on the Ocrevus franchise and the broader multiple sclerosis (MS) pipeline [4][6]. Core Points and Arguments Fenebrutinib and Ocrevus - Fenebrutinib is positioned as a potential first-in-class and best-in-class treatment for both relapsing multiple sclerosis (RMS) and PPMS, with a dual mechanism of action targeting both relapsing and progressive disease biology [15][39]. - Ocrevus remains the leading treatment for MS, with 450,000 patients currently treated. It is the first and only twice-yearly anti-CD20 approved for both RMS and PPMS [7][10]. - The FENtrepid study demonstrated non-inferiority of fenebrutinib compared to ocrelizumab (Ocrevus) in reducing disability progression, achieving a 12% risk reduction in confirmed disability progression [27][39]. Clinical Data and Pipeline Updates - The FENtrepid study involved a well-established PPMS population, with a low presence of gadolinium-enhancing lesions, indicating a focus on progressive disease biology [25][26]. - Fenebrutinib showed a significant reduction in relapse rates, with approximately one relapse every 17 years reported in the FENhance 2 study [18]. - The MS pipeline includes other promising treatments, such as prasinezumab for Parkinson's disease and trontinemab for Alzheimer's disease, indicating a broad focus on neurodegenerative diseases [12][13]. Safety and Efficacy Concerns - There were concerns regarding liver enzyme elevations, with a higher frequency observed in the fenebrutinib arm compared to ocrelizumab. However, the majority of liver enzyme elevations resolved, and no confirmed Hy's Law cases were reported [32][35][39]. - Fatal events were reported in the fenebrutinib group, but investigators assessed them as unrelated to the study drug [33][39]. Additional Important Insights - The call highlighted the unmet medical need in MS, with about 30% of patients remaining on low-efficacy treatments and continuing to progress, underscoring the demand for new therapies [13][14]. - Fenebrutinib is expected to provide an oral treatment option, which may appeal to patients who prefer not to undergo infusions or injections [62][64]. - The potential for fenebrutinib to address both relapsing and progressive disease components positions it uniquely in the market, especially as the first oral high-efficacy treatment for both RMS and PPMS [64]. Conclusion - The conference call provided a comprehensive overview of fenebrutinib's clinical data, its positioning against existing treatments like Ocrevus, and the broader MS pipeline. The results from the FENtrepid study are promising, indicating potential for fenebrutinib to become a significant player in the treatment landscape for multiple sclerosis. The safety profile, particularly regarding liver enzyme elevations, will require ongoing monitoring as the drug moves closer to potential approval.